LUMICKS Competitors and Similar CompaniesClear all

LUMICKS's competitors and similar companies include ACEA Biosciences, Fluidic Analytics and PredictImmune.
LUMICKS
LUMICKS
LUMICKS is a supplier of dynamic single-molecule and cell avidity analysis instruments.
ACEA Biosciences
ACEA Biosciences
ACEA Biosciences is a company developing cell analysis platforms for life science research.
Fluidic Analytics
Fluidic Analytics
Fluidic Analytics designs, develops, and manufactures tools for the characterization of proteins in laboratory, medical, and consumer applications.
PredictImmune
PredictImmune
PredictImmune is a developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases.
Founding Date
Founding Date
2014
Founding Date
2002
Founding Date
2013
Founding Date
2017
Type
Type
Private
Type
Subsidiary
Type
Private
Type
Private
Tags
Locations
Locations
Amsterdam, NL HQ
Waltham, US
Locations
San Diego, US HQ
Hangzhou, CN
Locations
Cambridgeshire, GB HQ
Schlieren, CH
Cambridge, GB
Woburn, US
Locations
Babraham, GB HQ
Cambridge, GB
London, GB
Employees
Employees
1561% decrease
Employees
582% decrease
Employees
9
Employees
13

Funding

Latest funding round
Latest funding round
$ 93m (about 5 years ago)
Latest funding round
N/A
Latest funding round
$ 31m (over 7 years ago)
Latest funding round
$ 13.4m (almost 7 years ago)
Total funding raised
Total funding raised
$ 93m
Total funding raised
$ 71m
Total funding raised
$ 40.5m
Total funding raised
$ 25.4m
For sources of this data, please see the company profile

View Company Profiles

ACEA Biosciences
HQ
San Diego, US

ACEA Biosciences is a company developing cell analysis platforms for life science research.

View company
Fluidic Analytics
HQ
Cambridgeshire, GB
Employees
9

Fluidic Analytics designs, develops, and manufactures tools for the characterization of proteins in laboratory, medical, and consumer applications.

View company
PredictImmune
HQ
Babraham, GB
Employees
13

PredictImmune is a developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases.

View company